The Aladote study in patients treated for paracetamol overdose proceeds into final dosage group
February 1, 2018
(Non-regulatory)
After completion of recruitment of the second dosage cohort and review by the data safety monitoring committee, the approval was given to initiate the 3rd and last cohort in the open-label, randomised, rising dose design, proof-of-principle safety and tolerability study with Aladote in patients treated with NAC for paracetamol overdose.
The study is conducted at the University of Edinburgh, Queen’s Medical Research Institute in Scotland and will involve a total of 24 patients assigned into one of 3 dosing cohorts of 8 patients.
